Clinical trial · no report yet · Phase 1/Phase 2
BEGONIA
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- NCT03742102 ↗
- Active not recruiting
- AstraZeneca
- 153 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 71 | |
| Podcasts | 55 | |
| X threads | 26 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active not recruiting
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Durvalumab; Capivasertib; Oleclumab; Paclitaxel; Trastuzumab deruxtecan; Datopotamab deruxtecan
- Arms
- Arm 1 · Experimental
- Arm 2 · Experimental
- Arm 5 · Experimental
- Arm 6 · Experimental
- Arm 7 · Experimental
- Arm 8 · Experimental
- Enrollment
- 243
- Primary outcomes
- Dose Limiting Toxicity (DLT) Events
- Sponsor
- AstraZeneca
- Start
- Dec 21, 2018
- Primary completion
- Nov 29, 2024
- Results posted
- Yes
- Registry record
- NCT03742102 · updated Aug 4, 2026
Publications
linked from the registry- Schmid P, Im SA, Nowecki Z, Wysocki PJ, Jassem J, Jung KH, Lord S, Armstrong J, Stewart R, Vukovic P, Denduluri N, Park YH. First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial. Nat Cancer. 2026 Jun;7(6):983-992. doi: 10.1038/s43018-026-01181-8. Epub 2026 Jun 8. PubMed 42259988